Overview

A comparatiVe Study on Efficacy and Safety of Lipegfilgrastim in Comparison to Pegfilgrastim in Elderly Patients With Aggressive B Cell Non-HOdgkin Lymphomas at hIgh Risk for R-CHOP-21-inDuced Neutropenia

Status:
Completed
Trial end date:
2018-04-24
Target enrollment:
Participant gender:
Summary
The primary objective of the study is to demonstrate non-inferiority of lipegfilgrastim to pegfilgrastim for the duration of severe neutropenia in the first cycle of chemotherapy.
Phase:
Phase 3
Details
Lead Sponsor:
Merckle GmbH